新疆妇女宫颈癌组织中HPV-16 E1/dup突变体分布的研究  

Study on Distribution of HPV-16 E1/dup Mutant in Xinjiang Women with Cervical Carcinoma

作　　者：侯向前[1] 史茜[1] 朱开春[2] 玛依努尔.尼亚孜 马正海[1] 

机构地区：[1]新疆大学生命科学与技术学院,新疆乌鲁木齐830046 [2]新疆自治区人民医院,新疆乌鲁木齐830001

出　　处：《新疆大学学报（自然科学版）》2012年第4期384-389,505,共6页Journal of Xinjiang University(Natural Science Edition)

基　　金：国家自然科学基金(31060025);新疆生物资源基因工程重点实验室开放课题

摘　　要：目的检测HPV-16 1311～1773位63bp重复序列插入突变的E1基因(E1/dup)在宫颈炎、宫颈上皮内瘤变(cervical intraepithelial neoplasia,CIN)及宫颈癌病变组织中的分布及病毒的整合状态,探讨该突变对病毒致癌活性的影响.方法收集维吾尔族和汉族宫颈炎、CIN和宫颈癌临床组织标本215例,提取组织DNA,PCR检测E1/dup突变体以及病毒E1/E2基因的完整性.结果新疆地区215例宫颈病变组织中HPV-16 E1检出率为60.00%(129/215),宫颈炎、CIN及宫颈癌病样中HPV-16 E1的检出率分别为31.15%(19/61)、49.21%(31/63)和86.81%(79/91).在HPV-16E1阳性病样中,HPV-16 E1/dup突变率为37.21%(48/129),宫颈炎、CIN和宫颈癌病样中E1/dup突变率分别为15.79%、22.58%和48.10%,E1/dup突变率在宫颈癌中显著高于宫颈炎(P<0.05)和CIN(P<0.05).E1/dup突变率在汉族和维吾尔族宫颈癌病样中分别为40.00%(6/15)和50.00%(32/64),两者无显著性差异(P>0.05).在HPV-16 E1阳性病样中病毒整合率为51.72%(60/116),E1/dup突变病样中HPV16整合率[69.05%(29/42)]明显高于未发生E1/dup突变的病样[41.89%(31/74)](P<0.05).结论新疆地区E1/dup突变率在宫颈癌中显著高于宫颈炎及CIN,E1/dup与病毒致癌活性及病毒整合相关.Objective To detect the distribution of HPV-16 E1 gene mutant with the insertion of 63bp nucleotide duplication sequences at position 1311-1373 （E1/dup） from clinical tissue specimens of cervicitis, cervical intraepithelial neoplasia （CIN） and cervical cancer, and define the integrated status of HPV-16, then research into the carciongenic potency of E1/dup. Methods 215 clinical tissue specimens of cervicitis, CIN and cervical cancer from Uygur and Han patients were collected, the tissue DNAs were extracted. Then E1/dup mutant and integral E1/E2 were detected by PCR. Results The positive rate of HPV-16 E1 in the 215 specimens was 60.00% （129/215）, and the rates in cervicitis, CIN and cervical cancer were 31.15% （19/61）, 49.21% （31/63） and 86.81% （79/91） respectively. In the HPV-16 E1 positive specimens, the rates of E1/dup mutant were 37.21%（48/129）, and the rate of E1/dup mutant from the cervical cancer （48.10%） was significantly higher than that from the cervicitis （15.79%） （P〈0.05） and CIN（22.58%） （P〈0.05）. The rates of E1/dup mutant from Han cervical cancer and Uygur cervical cancer specimens were 40.00% （6/15） and 50.00% （32/64） respectively, there were no significant differences between of them （P〉0.05）. The rate of integrated HPV-16 from the E1 positive specimens was 51.72%（60/119）, and the rate[69.05%（29/42）] from the E1/dup Specimens was significantly higher than the rate [41.89%（31/74）] from no-E1/dup Specimens. Conclusion The rate of E1/dup mutant from the cervical cancer was significantly higher than that from the cervicitis and CIN, and E1/dup mutant was associated with the carciongenic potency and integrated status of HPV-16.

关 键 词：HPV-16 宫颈癌 E1 dup突变体 致癌能力 

分 类 号：Q78[生物学—分子生物学]